STAMBP and pachyonychia congenita: Increasing evidence has shown that STAMBP is highly elevated and is linked to poor clinical prognosis in multiple cancers, such as lung adenocarcinoma, breast cancer, triple-negative breast cancer, and PC [19, 20, 22].